The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
Deronic, Adnan, Nilsson, Anneli, Thagesson, Mia, Werchau, Doreen, Enell Smith, Karin, Ellmark, Peter
Published in Cancer Immunology, Immunotherapy (01.12.2021)
Published in Cancer Immunology, Immunotherapy (01.12.2021)
Get full text
Journal Article
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
Enell Smith, Karin, Fritzell, Sara, Nilsson, Anneli, Barchan, Karin, Rosén, Anna, Schultz, Lena, Varas, Laura, Säll, Anna, Rose, Nadia, Håkansson, Maria, von Schantz, Laura, Ellmark, Peter
Published in Cancer Immunology, Immunotherapy (01.12.2023)
Published in Cancer Immunology, Immunotherapy (01.12.2023)
Get full text
Journal Article
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
Van Laethem, Jean-Luc, Borbath, Ivan, Prenen, Hans, Geboes, Karen Paula, Lambert, Aurélien, Mitry, Emmanuel, Cassier, Philippe Alexandre, Blanc, Jean-Frédéric, Pilla, Lorenzo, Batlle, Jaime Feliu, Garrote, Mercedes Rodriguez, Pazo-Cid, Roberto Antonio, Gallego, Inmaculada, Smith, Karin Enell, Ellmark, Peter, Pico de Coaña, Yago, Ambarkhane, Sumeet Vijay, Macarulla, Teresa
Published in The lancet oncology (01.07.2024)
Published in The lancet oncology (01.07.2024)
Get full text
Journal Article
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Kvarnhammar, Anne Månsson, Veitonmäki, Niina, Hägerbrand, Karin, Dahlman, Anna, Smith, Karin Enell, Fritzell, Sara, von Schantz, Laura, Thagesson, Mia, Werchau, Doreen, Smedenfors, Kristine, Johansson, Maria, Rosén, Anna, Åberg, Ida, Winnerstam, Magnus, Nyblom, Eva, Barchan, Karin, Furebring, Christina, Norlén, Per, Ellmark, Peter
Published in Journal for immunotherapy of cancer (11.04.2019)
Published in Journal for immunotherapy of cancer (11.04.2019)
Get full text
Journal Article
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
Andersson, Hampus, Sobti, Aastha, Jimenez, David Gomez, de Coaña, Yago Pico, Ambarkhane, Sumeet Vijay, Hägerbrand, Karin, Smith, Karin Enell, Lindstedt, Malin, Ellmark, Peter
Published in Cells (Basel, Switzerland) (27.09.2023)
Published in Cells (Basel, Switzerland) (27.09.2023)
Get full text
Journal Article
Postimmunization with IFN-gamma-secreting glioma cells combined with the inducible nitric oxide synthase inhibitor mercaptoethylguanidine prolongs survival of rats with intracerebral tumors
Badn, Wiaam, Visse, Edward, Darabi, Anna, Smith, Karin Enell, Salford, Leif G, Siesjö, Peter
Published in Journal of Immunology (15.09.2007)
Published in Journal of Immunology (15.09.2007)
Get full text
Journal Article
Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells
Smith, Karin Enell, Fritzell, Sara, Badn, Wiaam, Eberstål, Sofia, Janelidze, Shorena, Visse, Edward, Darabi, Anna, Siesjö, Peter
Published in International journal of cancer (01.02.2009)
Published in International journal of cancer (01.02.2009)
Get full text
Journal Article
The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice
Mangsbo, Sara M, Veitonmäki, Niina, Gustfson, Erika, Smith, Karin, Furebring, Christina, Norlén, Per, Lindstedt, Malin, Tötterman, Thomas H, Ellmark, Peter
Published in Journal for immunotherapy of cancer (06.11.2014)
Published in Journal for immunotherapy of cancer (06.11.2014)
Get full text
Journal Article
Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas
Janelidze, Shorena, Bexell, Daniel, Badn, Wiaam, Darabi, Anna, Smith, Karin-Enell, Fritzell, Sara, Gunnarsson, Salina, Milos, Peter, Bengzon, Johan, Salford, Leif Göran, Siesjö, Peter, Visse, Edward
Published in Journal of immunotherapy (1997) (01.07.2009)
Published in Journal of immunotherapy (1997) (01.07.2009)
Get more information
Journal Article
Abstract 1593: Mitazalimab, a potent CD40 agonist with potential for combination with chemotherapy
Deronic, Adnan, Thagesson, Mia, Nilsson, Anneli, Ellmark, Peter, Fält, Anette, Fält, Charlotte, Smith, Karin Enell
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
Mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (PDAC): Safety data from part of the OPTIMIZE-1 study
Van Laethem, Jean-Luc, Borbath, Ivan, Prenen, Hans, Pico de Coaña, Yago, Enell Smith, Karin, Nordbladh, Karin, Ellmark, Peter, Ambarkhane, Sumeet Vijay, Carlsson, Malin, Cassier, Philippe Alexandre
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies
Ullenhag, Gustav J., Carneiro, Ana, Enell Smith, Karin, Schultz, Lena, Ambarkhane, Sumeet Vijay, Landstrom, Tova, Yachnin, Jeffrey
Published in JOURNAL OF CLINICAL ONCOLOGY (01.06.2022)
Published in JOURNAL OF CLINICAL ONCOLOGY (01.06.2022)
Get full text
Journal Article
Conference Proceeding
Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study
Prenen, Hans, Borbath, Ivan, Geboes, Karen Paula, Cassier, Philippe Alexandre, Lambert, Aurélien, Mitry, Emmanuel, Macarulla, Teresa, Taieb, Julien, Blanc, Jean-Frédéric, Feliu Batlle, Jaime, Rodríguez Garrote, Mercedes, Pazo Cid, Roberto A., Valladares-Ayerbes, Manuel, Nordbladh, Karin, Enell Smith, Karin, Ellmark, Peter, Carlsson, Malin, Pico de Coaña, Yago, Ambarkhane, Sumeet Vijay, Van Laethem, Jean-Luc
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies
Ullenhag, Gustav J., Yachnin, Jeffrey, Carneiro, Ana, Elison, Emma, Carlsson, Malin, Russell, Charlotte Astrid, Enell Smith, Karin
Published in JOURNAL OF CLINICAL ONCOLOGY (20.05.2021)
Published in JOURNAL OF CLINICAL ONCOLOGY (20.05.2021)
Get full text
Journal Article
Conference Proceeding
Abstract 4077: ATOR-1144 is a tumor-directed CTLA-4 x GITR bispecific antibody that acts by depleting Tregs and activating effector T cells and NK cells
Fritzell, Sara, Levin, Mattias, Åberg, Ida, Johansson, Maria, Winnerstam, Magnus, Smith, Karin Enell, Ellmark, Peter, Furebring, Christina, Norlén, Per, Kvarnhammar, Anne
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
Abstract 2376: Mitazalimab, a potent CD40 agonist in combination with FOLFIRINOX demonstrates changes consistent with increased immune activation in TME and peripheral blood in a preclinical pancreatic cancer tumor model
Smith, Karin Enell, Jimenez, David Gomez, Thagesson, Mia, Nilsson, Anneli, de Coaña, Yago Pico, Ambarkhane, Sumeet, Ellmark, Peter
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article